Search research articles
Contact Us
Filters
Showing results (241-250 of 309) with videos related to
Page
of 31
Sort By:
Journal of Cancer Research and Clinical Oncology
|
March 24, 2021
Antihormone treatment differentially regulates PSA secretion, PSMA expression and <sup>68</sup>Ga-PSMA uptake in LNCaP cells
C S Mathy, T Mayr, S Kürpig, et al.
Clinical Nuclear Medicine
|
April 19, 2022
Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor-Directed Molecular Imaging and Therapy
Sebastian E Serfling, Philipp E Hartrampf, Yingjun Zhi, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
January 15, 2019
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice
Sabina Dizdarevic, Peter Meidahl Petersen, Markus Essler, et al.
Nuklearmedizin. Nuclear Medicine
|
July 13, 2021
Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours
Barbara Kreppel, Maria Angeles Gonzalez-Carmona, Georg Feldmann, et al.
Oncotargets and Therapy
|
October 17, 2017
Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experience
Carsten Meyer, Claus Christian Pieper, Hojjat Ahmadzadehfar, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
July 19, 2022
mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease
Philipp E Hartrampf, Ralph A Bundschuh, Franz-Xaver Weinzierl, et al.
Trials
|
March 6, 2023
DEPROMP Trial: the additive value of PSMA-PET/CT-guided biopsy for prostate cancer management in biopsy naïve men-study protocol for a randomized trial
P Krausewitz, R A Bundschuh, F C Gaertner, et al.
Der Urologe. Ausg. A
|
August 18, 2021
[Interdisciplinary expert consensus on innovations in imaging diagnostics and radionuclide-based therapies for advanced prostate cancer]
Dirk Beyersdorff, Kambiz Rahbar, Markus Essler, et al.
Plos One
|
May 30, 2009
Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells
Enken Drecoll, Florian C Gaertner, Matthias Miederer, et al.
International Journal of Colorectal Disease
|
December 4, 2008
The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT
Robert Rosenberg, Ken Herrmann, Ralf Gertler, et al.
Page
of 31
Search research articles
Search
Showing results (241-250 of 309) with videos related to
Sort By:
Page
of 31
Journal of Cancer Research and Clinical Oncology
|
March 24, 2021
Antihormone treatment differentially regulates PSA secretion, PSMA expression and <sup>68</sup>Ga-PSMA uptake in LNCaP cells
C S Mathy, T Mayr, S Kürpig, et al.
Clinical Nuclear Medicine
|
April 19, 2022
Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor-Directed Molecular Imaging and Therapy
Sebastian E Serfling, Philipp E Hartrampf, Yingjun Zhi, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
January 15, 2019
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice
Sabina Dizdarevic, Peter Meidahl Petersen, Markus Essler, et al.
Nuklearmedizin. Nuclear Medicine
|
July 13, 2021
Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours
Barbara Kreppel, Maria Angeles Gonzalez-Carmona, Georg Feldmann, et al.
Oncotargets and Therapy
|
October 17, 2017
Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experience
Carsten Meyer, Claus Christian Pieper, Hojjat Ahmadzadehfar, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
July 19, 2022
mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease
Philipp E Hartrampf, Ralph A Bundschuh, Franz-Xaver Weinzierl, et al.
Trials
|
March 6, 2023
DEPROMP Trial: the additive value of PSMA-PET/CT-guided biopsy for prostate cancer management in biopsy naïve men-study protocol for a randomized trial
P Krausewitz, R A Bundschuh, F C Gaertner, et al.
Der Urologe. Ausg. A
|
August 18, 2021
[Interdisciplinary expert consensus on innovations in imaging diagnostics and radionuclide-based therapies for advanced prostate cancer]
Dirk Beyersdorff, Kambiz Rahbar, Markus Essler, et al.
Plos One
|
May 30, 2009
Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells
Enken Drecoll, Florian C Gaertner, Matthias Miederer, et al.
International Journal of Colorectal Disease
|
December 4, 2008
The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT
Robert Rosenberg, Ken Herrmann, Ralf Gertler, et al.
Page
of 31